| PE TTM | 28.4Sector 46.1 |
|---|---|
| 1-Year Return | 53.98%Price change |
| Promoter Holding | 74.85%No pledge |
| RSI | 60.86Neutral Zone |
| Metric | Q2-27 | Q1-27 | Q2-26 |
|---|---|---|---|
| Revenue from Operations | 682 | 640 | 588 |
| Other Income | 19.9 | 22.4 | 14.7 |
| Total Income | 702 | 663 | 603 |
| Profit Before Tax | 262 | 212 | 174 |
| Net Profit | 197 | 160 | 130 |
| Operating Margin | 37.3% | 32.0% | 28.9% |
| Net Profit QoQ | +22.9% | ||
| Net Profit YoY | +51.3% | ||
| Adj. Profit QoQ | +27.6% | ||
| Adj. Profit YoY | +51.9% | ||
Key highlights
- Net profit rose 51.3% YoY to ₹197 crore from ₹130 crore in the same period last year
- Revenue from operations reached ₹682 crore, a 16% increase over Q2 FY26
- Operating margins expanded to 37.3%, up from 28.9% in the year-ago quarter
- Profit before tax surged 50.6% YoY to reach ₹262 crore
- The company incorporated a new wholly-owned subsidiary in Brazil on September 15, 2026
- Paid-up equity share capital increased to ₹245.54 million following an ESOP allotment of 32,000 shares
Robust Profitability and Margin Expansion
Alivus Life Sciences Limited, formerly Glenmark Life Sciences, reported a net profit of ₹197 crore for the second quarter ended September 30, 2026, marking a 51.3% increase compared to ₹130 crore in the same period last year. Revenue from operations climbed 16% YoY to ₹682 crore, supported by robust demand in its core API business. The company achieved a notable improvement in its operating margin, which expanded to 37.3% from 28.9% in Q2 FY26.
On a sequential basis, net profit grew by 22.9% from ₹160 crore in the June 2026 quarter, indicating sustained operational momentum throughout the first half of the fiscal year.
Strategic Expansion and Corporate Updates
- Incorporated Alivus Life Sciences Do Brasil Ltda. as a wholly-owned subsidiary in Sao Paulo, Brazil, on September 15, 2026
- Confirmed Active Pharmaceutical Ingredient (API) remains the company's sole reporting segment
- Completed the allotment of 32,000 equity shares under the Employee Stock Option Scheme 2021 during the quarter
- Reported consolidated other income of ₹19.9 crore, contributing to a total income of ₹702 crore
- Board meeting for result approval commenced at 5.10 p.m. and concluded at 6.15 p.m. on October 29, 2026
Market Performance and Valuation Context
The company currently trades at a TTM price-to-earnings (P/E) ratio of 28.4, which sits significantly lower than the industry P/E of 45.81. This valuation gap comes despite a 1-year price appreciation of 53.98%, reflecting the stock's transition to what is classified as a strong performer. The company maintains a healthy durability score of 60 and a normalized momentum score of 75.72.
With a market capitalization of ₹17,126.61 crore and a stable promoter holding of 74.85%, Alivus appears positioned to leverage its high-potency API pipeline which targets a total addressable market estimated at $70 billion.
| Date | Announcement | Amount |
|---|---|---|
| 30 Jul 2026 | FY27 revenue growth guidance of 10% to 12% and EBITDA margin of 30% to 32%Source: univest.in | – |
| 30 Jul 2026 | Q1 FY27 standalone revenue from operationsSource: sahi.com | ₹640.41 Cr |
| 14 May 2026 | Q4 FY26 standalone revenue from operationsSource: torusdigital.com | ₹689.12 Cr |
| 22 Jan 2026 | FY26 revised capital expenditure guidanceSource: scanx.trade | ₹450.00 Cr |
| 22 Jan 2026 | Q3 FY26 standalone revenue from operationsSource: youtube.com | ₹672.89 Cr |
| 06 Nov 2025 | Q2 FY26 standalone revenue from operationsSource: moizz.in | ₹587.98 Cr |
What to watch next
- Earnings call scheduled for October 30, 2026, to discuss Q2 FY27 performance
- Updates on the commercial commissioning of Phase 1 of the Solapur greenfield API facility
- Commencement of operations and first transactions at the newly formed Brazil subsidiary
- Progress on the active development pipeline of 27 high-potency API (HP API) products
| Share price | ₹1395 |
|---|---|
| Market capitalisation | ₹17,126.61 Cr |
| Revenue (annual) | ₹2,551.83 Cr |
| Net profit (annual) | ₹564.48 Cr |
| Revenue (latest quarter) | ₹640.41 Cr-7.07% vs previous quarter |
| Net profit (latest quarter) | ₹160.08 Cr-1.59% vs previous quarter |
| P/E (TTM) | 28.4×Sector 46.08× |
| Promoter holding | 74.85%-0.02% QoQ |
| FII holding | 5.93%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Alivus Life Sciences Limited announcing unaudited financial results for the quarter and half-year ended September 30, 2026. Market figures from a third-party data provider.
